SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

DOI: 10.1016/j.cell.2021.12.046

Authors: Wanwisa Dejnirattisai (Wellcome Centre for Human Genetics, University of Oxford) , Jiandong Huo (Wellcome Centre for Human Genetics, University of Oxford) , Daming Zhou (Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Jiří Zahradník (Weizmann Institute of Science) , Piyada Supasa (Wellcome Centre for Human Genetics, University of Oxford) , Chang Liu (Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Helen M. E. Duyvesteyn (Wellcome Centre for Human Genetics, University of Oxford) , Helen M. Ginn (Diamond Light Source) , Alexander J. Mentzer (Wellcome Centre for Human Genetics, University of Oxford; Oxford University Hospitals NHS Foundation Trust) , Aekkachai Tuekprakhon (Wellcome Centre for Human Genetics, University of Oxford) , Rungtiwa Nutalai (Wellcome Centre for Human Genetics, University of Oxford) , Beibei Wang (Wellcome Centre for Human Genetics, University of Oxford) , Aiste Dijokaite (Wellcome Centre for Human Genetics, University of Oxford) , Suman Khan (Weizmann Institute of Science) , Ori Avinoam (Weizmann Institute of Science) , Mohammad Bahar (Wellcome Centre for Human Genetics, University of Oxford) , Donal Skelly (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research; University of Oxford) , Sandra Adele (Peter Medawar Building for Pathogen Research) , Sile Ann Johnson (Peter Medawar Building for Pathogen Research) , Ali Amini (Oxford University Hospitals NHS Foundation Trust; University of Oxford; Peter Medawar Building for Pathogen Research) , Thomas Ritter (Oxford University Hospitals NHS Foundation Trust) , Chris Mason (Oxford University Hospitals NHS Foundation Trust) , Christina Dold (NIHR Oxford Biomedical Research Centre; University of Oxford) , Daniel Pan (University Hospitals of Leicester NHS Trust; University of Leicester) , Sara Assadi (University Hospitals of Leicester NHS Trust) , Adam Bellass (University Hospitals of Leicester NHS Trust) , Nikki Omo-Dare (University Hospitals of Leicester NHS Trust) , David Koeckerling (University of Oxford) , Amy Flaxman (Jenner Institute, University of Oxford) , Daniel Jenkin (Jenner Institute, University of Oxford) , Parvinder K. Aley (University of Oxford) , Merryn Voysey (University of Oxford) , Sue Ann Costa Clemens (University of Siena; University of Oxford) , Felipe Gomes Naveca (Instituto Leônidas e Maria Deane) , Valdinete Nascimento (Instituto Leônidas e Maria Deane) , Fernanda Nascimento (Instituto Leônidas e Maria Deane) , Cristiano Fernandes Da Costa (Fundação de Vigilância em Saúde do Amazonas) , Paola Cristina Resende (Laboratorio de vírus respiratórios- IOC/FIOCRUZ) , Alex Pauvolid-Correa (Laboratorio de vírus respiratórios- IOC/FIOCRUZ; Texas A&M University) , Marilda M. Siqueira (Laboratorio de vírus respiratórios- IOC/FIOCRUZ) , Vicky Baillie (University of the Witwatersrand) , Natali Serafin (University of the Witwatersrand) , Gaurav Kwatra (University of the Witwatersrand) , Kelly Da Silva (University of the Witwatersrand) , Shabir A. Madhi (University of the Witwatersrand) , Marta C. Nunes (University of the Witwatersrand) , Tariq Malik (Public Health England (PHE)) , Peter J. M. Openshaw (Imperial College London) , J. Kenneth Baillie (University of Edinburgh) , Malcolm G. Semple (University of Liverpool) , Alain R. Townsend (Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford; John Radcliffe Hospital) , Kuan-Ying A. Huang (Chang Gung University) , Tiong Kit Tan (John Radcliffe Hospital) , Miles W. Carroll (Wellcome Centre for Human Genetics, University of Oxford; Public Health England (PHE)) , Paul Klenerman (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research; University of Oxford; NIHR Oxford Biomedical Research Centre) , Eleanor Barnes (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research; University of Oxford; NIHR Oxford Biomedical Research Centre) , Susanna J. Dunachie (Oxford University Hospitals NHS Foundation Trust; Peter Medawar Building for Pathogen Research; University of Oxford; Mahidol-Oxford Tropical Medicine Research Unit) , Bede Constantinides (University of Oxford) , Hermione Webster (University of Oxford) , Derrick Crook (University of Oxford) , Andrew J. Pollard (NIHR Oxford Biomedical Research Centre; University of Oxford) , Teresa Lambe (Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford) , Neil G. Paterson (Diamond Light Source) , Mark A. Williams (Diamond Light Source) , David R. Hall (Diamond Light Source) , Elizabeth E. Fry (Wellcome Centre for Human Genetics, University of Oxford) , Juthathip Mongkolsapaya (Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford; Mahidol University) , Jingshan Ren (Wellcome Centre for Human Genetics, University of Oxford) , Gideon Schreiber (Weizmann Institute of Science) , David I. Stuart (Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford; Diamond Light Source; Instruct-ERIC) , Gavin R. Screaton (Wellcome Centre for Human Genetics, University of Oxford; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford)
Co-authored by industrial partner: No

Type: Journal Paper
Journal: Cell

State: Published (Approved)
Published: January 2022
Diamond Proposal Number(s): 27009

Abstract: On the 24th November 2021 the sequence of a new SARS CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize. Titres against Omicron are boosted by third vaccine doses and are high in cases both vaccinated and infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of a large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses, combining mutations conferring tight binding to ACE2 to unleash evolution driven by immune escape, leading to a large number of mutations in the ACE2 binding site which rebalance receptor affinity to that of early pandemic viruses.

Diamond Keywords: COVID-19; Viruses

Subject Areas: Biology and Bio-materials, Medicine


Instruments: I03-Macromolecular Crystallography

Added On: 04/01/2022 14:57

Discipline Tags:

Vaccines Pathogens Infectious Diseases Health & Wellbeing Structural biology Life Sciences & Biotech

Technical Tags:

Diffraction Macromolecular Crystallography (MX)